France-based Kinnov Therapeutics has announced results from its randomised, placebo-controlled Phase II clinical trial showed that KT-110 demonstrated superior efficacy in reducing alcohol consumption among the trial’s 154 participants.
KT-110 is a combination of cyproheptadine and prazosin and can be delivered effectively via a one-a-day tablet. The drug works by simultaneously modulating the noradrenergic and serotonergic brain receptors that work against the neurobiological processes responsible for causing addiction.
Patients treated with KT-110 achieved a reduction in alcohol consumption by 26 to 30 grams compared to the placebo. The equivalent of two and a half to three drinks.
Kinnov’s CEO Emmanuel de Rivoire said: " Alcohol dependence, or AUD, is a serious public health issue and the medical need for the treatment of alcoholism is considerable and unmet: no new drug has been brought to market since 2013. Alcoholism is a crippling disease that is prohibitively expensive to treat and causes three million deaths every year.”
De Rivoire added “With KT-110, we hope to make a real difference in the care and quality of life of patients suffering from the severe consequences of alcoholism. Armed with these promising results, we are now seeking a commercial pharmaceutical partner to continue the development and commercialisation of KT110 and enable patients to gain access to this innovative treatment.”
GlobalData’s Pharmaceutical Intelligence Centre estimates the total global market for drugs relating to alcohol dependence at $3bn by 2029, up from a total global sales of $596m in 2022. Additionally, there are currently 485 drugs marketed in the indication, with an additional 142 treatments currently in development.
GlobalData is the parent company of Clinical Trials Arena.
Clinical Trials Arena has previously explored the possible reasons behind the lack of pharma sponsorship in clinical trials investigating new addiction treatments.
